Regenerative Medicine Market Size is valued at 34.77 billion in 2024 and is predicted to reach 141.87 billion by the year 2034 at a 15.2% CAGR during the forecast period for 2025-2034.
The preference for individualized therapeutic approaches over conventional treatment modalities has changed due to several developments in biological therapy. For those in the market working on creating natural treatments, this has opened up a lot of prospects. Numerous developments in biological therapeutics have shifted the preference towards personalized medicinal strategies over traditional treatment methods, resulting in the Regenerative Medicine market expansion.
The COVID-19 pandemic has significantly influenced several businesses, notably the T-cell therapies and regenerative medicine industry. The SARS-CoV-2 coronavirus outbreak has dramatically impacted the delivery of CAR T-cell therapy. This effect has spread beyond patient care to include administration, logistics, and the scarcity of healthcare resources. Clinical trial enrolment and other research activity have slowed down at some universities. Yet, as market participants like Novartis continue to open up access to treatments like MultiStem, a very relevant COVID-19 medication from Athersys, Inc., the market continues to grow.
The Regenerative Medicine market is segmented based on product and therapeutic category. Based on product, the market is segmented as Therapeutics, Primary cell-based therapeutics, Stem Cell & Progenitor Cell-based therapeutics. By therapeutics category, the market is segmented into Dermatology, Musculoskeletal, Immunology & Inflammation, and Oncology.
Due to the growing elderly population and more excellent incidence rates of age-related and degenerative illnesses, the therapeutics category held the most significant revenue share of the regenerative medicine market. Researchers have been inspired to create alternative solutions by the rising prevalence of diseases for which there are no effective treatments, including cancer, diabetes, and neurodegenerative illnesses like AMD. For instance, Kite, a Gilead Company, declared in April 2022 that the U.S. FDA had approved Yescarta, a CAR T-cell therapy product, for treating refractory or relapsed large B-cell lymphoma.
Due to the rising incidence of cancer worldwide, the oncology segment led the market for regenerative medicine. Numerous governmental agencies and private businesses have invested much in cancer research and the creation of cutting-edge cell therapies. A partnership agreement between Calidi Biotherapeutics (CBT) and First Light Acquisition Group (FLAG) was signed in January 2023 with the intention of using stem cell-based platforms to revolutionize oncolytic virotherapies.
North America controlled the market for regenerative medicine. The significant regenerative medicine market growth is attributable to the availability of public and private development financing, the existence of cutting-edge technological frameworks to assist the quick detection of chronic diseases, and the high healthcare spending in the area. In addition, the region has grown as a result of numerous ongoing clinical trials for regenerative medicine by important industry players. To prevent acute graft versus host disease in adults and paediatric patients two years of age and older undergoing hematopoietic stem cell transplantation, Bristol Myers Squibb acquired U.S. FDA approval for Orencia in December 2021. (HSCT).
|
Report Attribute |
Specifications |
|
Market size value in 2023 |
USD 34.77 Bn |
|
Revenue forecast in 2031 |
USD 141.87 Bn |
|
Growth rate CAGR |
CAGR of 15.2% from 2025 to 2034 |
|
Quantitative units |
Representation of revenue in US$ Million, and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
|
Segments covered |
Product And Therapeutic Category |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; South Korea; Southeast Asia |
|
Competitive Landscape |
AstraZeneca plc; F. Hoffmann-La Roche Ltd.; Integra Lifesciences Corp.; Astellas Pharma, Inc.; Cook Biotech, Inc.; Bayer AG; Pfizer, Inc.; Merck KGaA; Abbott; Vericel Corp.; Novartis AG; GlaxoSmithKline (GSK); Baxter International, Inc.; Boehringer Ingelheim; Amgen, Inc.; Cesca Therapeutics, Inc.; U.S. Stem Cell, Inc.; Bristol-Myers Squibb; Eli Lilly and Company; NuVasive, Inc.; Organogenesis, Inc.; MiMedx Group, Inc.; Takara Bio, Inc.; Osiris Therapeutics, Inc.; Corline Biomedical AB. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Regenerative Medicine Market Snapshot
Chapter 4. Global Regenerative Medicine Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Product Type Estimates & Trend Analysis
5.1. by Product Type & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Product Type:
5.2.1. Therapeutics
5.2.1.1. Primary cell-based therapeutics
5.2.1.1.1. Dermatology
5.2.1.1.2. Musculoskeletal
5.2.1.1.3. Surgical
5.2.1.1.4. Dental
5.2.1.1.5. Others
5.2.1.2. Stem Cell & Progenitor Cell-based therapeutics
5.2.1.2.1. Autologous
5.2.1.2.2. Allogenic
5.2.1.2.3. Others
5.2.1.3. Cell-based Immunotherapies
5.2.1.4. Gene Therapies
5.2.2. Tools
5.2.3. Banks
5.2.4. Services
Chapter 6. Market Segmentation 2: by Therapeutic Estimates & Trend Analysis
6.1. by Therapeutic & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Therapeutic:
6.2.1. Dermatology
6.2.2. Musculoskeletal
6.2.3. Immunology & Inflammation
6.2.4. Oncology
6.2.5. Cardiovascular
6.2.6. Ophthalmology
6.2.7. Others
Chapter 7. Regenerative Medicine Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Regenerative Medicine Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2021-2034
7.1.2. North America Regenerative Medicine Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic, 2021-2034
7.1.3. North America Regenerative Medicine Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe Regenerative Medicine Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2021-2034
7.2.2. Europe Regenerative Medicine Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic, 2021-2034
7.2.3. Europe Regenerative Medicine Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Regenerative Medicine Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2021-2034
7.3.2. Asia Pacific Regenerative Medicine Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic, 2021-2034
7.3.3. Asia Pacific Regenerative Medicine Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Regenerative Medicine Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2021-2034
7.4.2. Latin America Regenerative Medicine Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic, 2021-2034
7.4.3. Latin America Regenerative Medicine Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Regenerative Medicine Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2021-2034
7.5.2. Middle East & Africa Regenerative Medicine Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic, 2021-2034
7.5.3. Middle East & Africa Regenerative Medicine Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. AstraZeneca plc
8.2.2. F. Hoffmann-La Roche Ltd.
8.2.3. Integra Lifesciences Corp.
8.2.4. Astellas Pharma, Inc.
8.2.5. Cook Biotech, Inc.
8.2.6. Bayer AG
8.2.7. Pfizer, Inc.
8.2.8. Merck KGaA
8.2.9. Abbott
8.2.10. Vericel Corp.
8.2.11. Novartis AG
8.2.12. GlaxoSmithKline (GSK)
8.2.13. Baxter International, Inc.
8.2.14. Boehringer Ingelheim
8.2.15. Amgen Inc.
8.2.16. Cesca Therapeutics, Inc.
8.2.17. U.S. Stem Cell, Inc.
8.2.18. Bristol-Myers Squibb
8.2.19. Eli Lilly and Company
8.2.20. NuVasive, Inc.
8.2.21. Organogenesis, Inc.
8.2.22. MiMedx Group, Inc.
8.2.23. Takara Bio, Inc.
8.2.24. Osiris Therapeutics, Inc.
8.2.25. Corline Biomedical AB
8.2.26. Other Prominent Players
Regenerative Medicine Market By Product-
Regenerative Medicine Market By Therapeutic Category-
Regenerative Medicine Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
